Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 18;17(11):e0277052. doi: 10.1371/journal.pone.0277052

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Kelsey et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 6 — a. Treatment plans for Case 3, a 16-year-old with a >8 cm unresectable Ewing sarcoma. b. Analysis and comparison of dose received by each ovary for Case 3, a 16-year-old with a >8 cm unresectable Ewing sarcoma. c. Comparison of treatment plans assuming average NGF population at age of treatment (i.e., z-score = 0) for Case 3, a 16-year-old with a >8 cm unresectable Ewing sarcoma. Dots are predicted age at menopause after mean dose. Fertility window ranges between predicted ages for minimum & maximum dose. LD₅₀ is estimated to be 2 Gy. Dose is to the least affected ovary. d. Comparison of treatment plans for Case 3, a 16-year-old with a >8 cm unresectable Ewing sarcoma that incorporate uncertainty due to variation in NGF population at birth. (Or, equivalently, variation in ages at menopause). The z-score 0 values are the same ranges as reported in Fig 6. 68% of the population are expected to fall in the left-to-right shaded area.